Absence of Antibody Responses and Severe COVID-19 in Patients on Hemodialysis Following mRNA Vaccination

Miriam B. Michael¹, Dept of Medicine, University Washington, DC USA “No Conflict”

Siham M. Mahgoub¹, Dept of Medicine, Howard University, Washington, DC USA “No Conflict”

Reiad Khan³, Dept of Medicine, Howard University, Washington, DC USA “No Conflict”

Thomas A. Mellman⁴, Dept of Psychiatry and Behavioral Sciences, Howard University, Washington, DC USA “No Conflict”

Constance C. Mere⁵, Dept of Medicine, Howard University, Washington, DC USA “No Conflict”

Alem Mehari⁶, Dept of Medicine, Howard University, Washington, DC USA “No Conflict”

Tammey J. Naab⁷, Dept of Pathology Howard University, Washington, DC USA “No Conflict”

Uzoamake Nwagwugwu⁸, Dept of Medicine, Howard University, Washington, DC USA “No Conflict”

Susan Ihaegwara⁹, Dept of Medicine, Howard University, Washington, DC USA “No Conflict”

Celia J. Maxwell Dept of Medicine¹⁰, Howard University, Washington, DC USA “No Conflict”

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Case Report of 2 dialysis patients who had COVID-19 infection post vaccination. Both patients did not mount antibody titers to the COVID-19 vaccine and were previously non-responders to the hepatitis B vaccine.

Correspondence

Siham Mahgoub, Georgia Ave NW, Washington DC 20060 siham.mahgoub@howard.edu phone: 202-865-7516 (Corresponding Author)

Miriam Michael, 2041 Georgia Ave NW, Washington DC 20060, m.michael@howard.edu, Cell 202-441-5561 fax 1-888-753-5366 (Alternate Corresponding Author)

Author Contributions

S.I., U.N., C.M were the patients’ nephrologists. A.M. was their intensivist. T.N. supervised the antibody and COVID tests. All four contributed to discussions of the cases and formulation of the report. M.M. and R.K. reviewed the literature and wrote the manuscript. S.M, T.M., S.Q., and C.M. reviewed and edited the manuscript.

*We would like to acknowledge the administrative support offered by Ms. Itala Michelli that has helped us during the preparation of this brief case report.
Abstract

Inpatient dialysis patients cannot isolate resulting in higher rate of COVID-19 infections, with increased severity and higher mortality rate [1] We present 2 African American dialysis patients who developed severe COVID-19 infections after vaccination. Both had not mounted antibody response to the COVID-19 vaccine, and to hepatitis B vaccination.

Keywords: COVID-19, Hepatitis B, ESRD, Vaccination, Non responder
Introduction

More than 3 million patients are receiving renal dialysis worldwide including greater than 746,000 in the United States. In-center hemodialysis patients have a high risk of viral exposure as well as risks related to multiple medical comorbidities and suppressed immunity. Hemodialysis patients are unable to isolate given the fact that they have to travel to the dialysis center 3 times a week, spending at least 3 to 4 hours in a dialysis session, and usually are around several other patients and staff [2]. Weiss etal have found in their study the COVID 19 prevalence rate of 14% among patients undergoing long-term dialysis compared to 2.6% in the New York City population [3]. In addition to increased rate of infection, there is increased mortality among those infected with the virus. In a study of 7948 dialysis patients in a 5-month period from February to June 2020 there were 438 (5.5%) diagnosed with COVID 19 of these 109(24.9%) died compared to 275 (3.7%) of 7510 hemodialysis patients who tested negative for COVID 19 [4]. Vaccine breakthrough cases are an area of interest with several recent papers addressing the issue of sub-optimal immune response among dialysis patients. Here we describe two cases of severe COVID infection that occurred in two fully vaccinated dialysis patients among the 99 vaccinated patients receiving dialysis at our center.

Case 1:

A 52-year-old African American female with end stage renal disease on dialysis and medical history of obesity, obstructive sleep apnea, antiphospholipid syndrome, prior history of bilateral pulmonary emboli and multiple deep venous thrombosis presented to the dialysis unit with 5 days of headache, myalgia, and progressive shortness of breath. She was sent to the emergency room where she was found to have COVID-19 based on polymerase chain reaction (PCR) testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2) RNA on nasopharyngeal sampling, which was confirmed on repeat PCR testing 2 days later. Her chest radiograph showed vascular congestion as well as superimposed patchy focal infiltrates, and she required high-flow oxygen via nasal cannula. On day 2 of her admission, she was transferred to the Intensive care unit and on day 3 of her ICU admission she developed cardiac arrest and expired.

Of note, she has completed COVID-19 vaccination with 2 doses of the Pfizer-BioNTech vaccine received 48 and 24 days before her admission. Serologic testing for Immunoglobulin G antibody against the SARS-CoV-2 spike protein from her second day of hospitalization revealed an index of <1.00 (a negative result).

Case 2:

A 70-year-old Ethiopian male with end stage renal disease on dialysis and history of atrial fibrillation, heart failure with preserved ejection fraction, recurrent transudative right pleural effusions, chronic obstructive pulmonary disease, diabetes mellitus, cerebrovascular accident, right lower extremity deep venous thrombosis and left atrial thrombus; developed shortness of breath, hypoxia and altered mental status while receiving dialysis. He was sent to the emergency room and was found to have COVID-19 based on polymerase chain reaction (PCR) testing for SARS-CoV-2 RNA on nasopharyngeal sampling. The diagnosis was confirmed on repeat PCR testing 2 days later and again 10 days later. He required non-invasive bi-level ventilation on presentation. He was eventually transferred to the intensive care unit where the patient was initially on non-invasive ventilation followed by mechanical ventilation and then expired secondary to respiratory failure. Like case 1, he has completed COVID-19 vaccination just over 3 weeks prior to his admission for COVID-19 pneumonia.
The patient was also tested on day 2 of hospitalization for Immunoglobulin G antibody against the SARS-CoV-2 spike protein which revealed an index of <1.00.

**Patient Consent**

Informed consent was obtained from the patient and or the patients’ designated representative for publication of this case report.

**Discussion**

The morbidity and mortality are very high in hemodialysis patients who develop COVID-19 infection; in addition, these patients do not develop adequate immune response to vaccination or infections [5] This is a case study of two African American patients with end stage renal disease receiving in-center maintenance hemodialysis who were vaccinated with Pfizer BioNTech COVID-19 vaccine more than 2 weeks after receiving the second dose who were hospitalized with COVID-19 pneumonia. The dialysis center where both patients were treated has 99 patients fully immunized (85%) of the patients in the dialysis unit. Among the 99 patients: 88 patients received Pfizer BioNTech COVID-19 vaccine, 8 patients received Moderna vaccine, and 3 patients received the Johnson & Johnson vaccine. Both patients did not mount neutralizing antibodies to COVID IgG spike protein using Semens Atellica Centaur platform when tested 25 days after their second vaccine dose. Both patients had also received the full series of the hepatitis B vaccine and had not mounted an antibody response.

A recent study of 56 patients on maintenance hemodialysis showed a positive humoral response in all but 2 cases following the BNT162b2 (Pfizer-BioNTech) vaccine, but antibody titers were significantly lower than in a healthy control group. Response was not related to the number of medical conditions of the study participants, but humoral responses did inversely correlate with age. [5] In our cases one of the patients was elderly.
Unique circumstances of in-center hemodialysis that increases the risk of patients getting COVID-19 also contribute to increased risk of hepatitis-B in the same population. The hepatitis B vaccine is usually administered intramuscularly in three doses (0, 1 and 6 months), with 95% of the population showing long lasting serologic immunity. An additional fourth dose or a repeated higher dose three course regimen is given to those that fail to show immunity. Despite these additional regimens, some patients remain vulnerable to hepatitis B and are deemed non-responders. [6] In a study of eighty-three dialysis patients who received the standard 20 micrograms of recombinant derived hepatitis B vaccine Engerix-B at 0, 1 and 6 months; twenty-seven (32.5%) were found to be seropositive for anti-HBs antibodies after receiving the third dose. There were 56 non responders, a booster dose of 40 micrograms was given to 48 patients 6 weeks after the initial course and 8 patients seroconverted [7]. In a study done by Agarwal et al, evaluating response rates to HBV vaccine in mild (creatinine 1.5 to 3.0 mg/dL), moderate (creatinine 3.0 to 6.0 mg/dL) and severe (creatinine > 6.0 mg/dL) chronic kidney disease, the seroconversion rates after 3 doses of 40 μg HBV vaccine double the standard dose; were 87.5%, 66.6% and 35.7%; Rates increased after a 4th dose was administered to 100%, 77% and 36.4%,[8].

DaRosa et al have demonstrated in a prospective cohort study that patients with low glomerular filtration rate, higher creatinine (late-stage kidney disease), diabetes, and old age are less likely to seroconvert [9]. For dialysis and immunosuppressed patients, the Center for Disease control recommends either giving a higher dose or increase the number of hepatitis B doses [10]

Renal failure patients have a significant drop in anti-HBs antibody titers with recommendations to have regular checks of anti-HBs status in vaccinated patients [10].
Conclusion

There is often a need for higher vaccine dosage or scheduling changes in hemodialysis patients [10]. These findings warrant close observation of patients with ESRD, including those who have been vaccinated, during the COVID 19 pandemic and further research on vaccination efficacy in this population.
**List of abbreviations:**

| Abbreviation | Description                      |
|--------------|----------------------------------|
| ESRD         | End-Stage Renal Disease          |
| SOB          | shortness of breath              |
| ICU          | Intensive Care Unit              |
| BUN          | Blood Urea Nitrogen              |
| INR          | International Normalized Ratio   |
| DVT          | Deep Vein Thrombosis             |
| CVA          | Cerebrovascular accident         |
| SARS         | Severe Acute Respiratory Syndrome|
References

1. Turgutalp, K., Ozturk, S., Arici, M., Eren, N., Gorgulu, N., Islam, M., ... & Ates, K. (2021). Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19. BMC nephrology, 22(1), 1-10.

2. Francis A, Baigent C, Ikizler TA, Cockwell P, Jha V. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. Kidney Int. 2021 Apr;99(4):791-793. doi: 10.1016/j.kint.2021.02.003. Epub 2021 Feb 12. PMID: 33582109; PMCID: PMC7879104.

3. Weiss S, Bhat P, Del Pilar Fernandez M, Bhat JG, Coritsidis GN. COVID-19 Infection in ESKD: Findings from a Prospective Disease Surveillance Program at Dialysis Facilities in New York City and Long Island. J Am Soc Nephrol. 2020 Nov;31(11):2517-2521. doi: 10.1681/ASN.2020070932. Epub 2020 Oct 19. PMID: 33077614; PMCID: PMC7608957.

4. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes from a National Dialysis Provider. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 2021 Jan. DOI: 10.1053/j.amjkd.2021.01.003.

5. Grupper, A., Sharon, N., Finn, T., Cohen, R., Israel, M., Agbaria, A., ... & Shashar, M. (2021). Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology.

6. Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine non responders: Possible mechanisms and solutions. Ann Allergy Asthma Immunol. 2018 Sep;121(3):320-327. doi: 10.1016/j.anai.2018.03.017. Epub 2018 Mar 19. PMID: 29567355.

7. Fleming SJ, Moran DM, Cooksley WG, Faoagali JL. Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect. 1991 May;22(3):251-7. doi: 10.1016/s0163-4453(05)80007-6. PMID: 1830073
8. Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate, and severe renal failure. J Assoc Physicians India. 1999; 47:183–185. [PubMed] [Google Scholar]

9. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, Kiaii M, Taylor PA, Levin A. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003; 42:1184–1192. [PubMed] [Google Scholar]

10. Centers for Disease Control. Guidelines for Vaccinating Kidney Dialysis Patients and Patients with Chronic Kidney Disease. Summary of ACIP Recommendations, December 2012. Updated Vaccine Guideline for Dialysis and Chronic Kidney Disease Patients